The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Managing patients with MPNs and co-existing inflammatory conditions or cardiovascular risks
Francesco Passamonti, MD, University of Milan, Milan, Italy, comments on the impact of co-existing inflammatory conditions or cardiovascular risks on patient outcomes and treatment plans in myeloproliferative neoplasms (MPNs). He highlights the importance of prophylaxis in reducing the risk of thrombosis and notes that lifestyle modifications are crucial in managing these high-risk diseases. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a quite important point because we know from the past that polycythemia vera and essential thrombocythemia are conditions at really high risk of thrombosis. And the inflammation and the link between molecular bases, inflammation, thrombosis, and progression of the disease in this condition is very clear. The most recent information says that we have vascular events also in myelofibrosis and the number of events is not dissimilar between PV, myelofibrosis, and ET...
This is a quite important point because we know from the past that polycythemia vera and essential thrombocythemia are conditions at really high risk of thrombosis. And the inflammation and the link between molecular bases, inflammation, thrombosis, and progression of the disease in this condition is very clear. The most recent information says that we have vascular events also in myelofibrosis and the number of events is not dissimilar between PV, myelofibrosis, and ET. So the prophylaxis with aspirin is quite relevant in this patient. And what about the ability of the new drug to reduce this point? Yes, of course, we have this possibility because we use in some of these patients agents with anti-inflammatory, anti-cytokine properties and this can reduce the risk of thrombosis. But of course, it’s quite important to have in mind that these are diseases at high risk of vascular events, so the lifestyle of the patient becomes very critical. So we have to discuss with our patients the issue of diet, the issue of practice and sport, and so on.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Abbvie: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; AOP: Honoraria, Speakers Bureau; GSK: Honoraria, Speakers Bureau; Karyiopharma: Honoraria, Speakers Bureau; Kyowa Kirin: Honoraria, Speakers Bureau; MEI: Honoraria, Speakers Bureau; Sumitomo: Honoraria, Speakers Bureau; BMS/Celgene: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Kartos Therapeutics Inc.: Honoraria, Speakers Bureau.
